首页> 外文OA文献 >Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney
【2h】

Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney

机译:OATP(SLC21 / SLCO),OAT和OCT(SLC22)和PEPT(SLC15)转运蛋白在肠,肝和肾中的药代动力学

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The role of carrier-mediated transport in determining the pharmacokinetics of drugs has become increasingly evident with the discovery of genetic variants that affect expression and/or function of a given drug transporter. Drug transporters are expressed at numerous epithelial barriers, such as intestinal epithelial cells, hepatocytes, renal tubular cells and at the blood-brain barrier. Several recent studies have associated alterations in substrate uptake with the presence of SNPs. Here, we summarize the current knowledge on the functional and phenotypic consequences of genetic variation in intestinally, hepatically and renally expressed members of the organic anion-transporting polypeptide family (OATPs; SLC21/SLCO family), the organic anion and organic cation transporters (OATs/OCTs; SLC22 family) and the peptide transporter-1 (PEPT1; SLC15 family).
机译:随着发现影响给定药物转运蛋白的表达和/或功能的遗传变异,载体介导的转运在确定药物的药代动力学中的作用变得越来越明显。药物转运蛋白表达于许多上皮屏障,例如肠上皮细胞,肝细胞,肾小管细胞和血脑屏障。最近的几项研究将底物摄取的改变与SNP的存在联系起来。在这里,我们总结了有关在有机,阴离子转运蛋白家族(OATP; SLC21 / SLCO家族),有机阴离子和有机阳离子转运蛋白(OAT)的肠,肝和肾中表达遗传变异的功能和表型后果的最新知识/ OCTs; SLC22家族)和肽转运蛋白1(PEPT1; SLC15家族)。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号